-27%

est. 2Y upside i

HealthcareSeries C

Rank

#1386

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Karius is a high-growth biotechnology company with an estimated current valuation of $950M and ~$75M in revenue, operating in a large and growing TAM.

Last updated: March 10, 2026

Bull (25%)+200%

Karius successfully expands its market reach beyond hospitals, launches new tests like Karius Focus™ | BAL, and achieves strong adoption in new indications, driving revenue to over $200M. This growth, coupled with progress towards profitability and leveraging its FDA Breakthrough Device designation, could justify a valuation of $2.85B, representing a 200% upside from the current estimated valuation.

Base (46%)+70%

Karius continues its steady growth, expanding its presence within existing hospital networks (currently over 400 U.S. hospitals) and making progress towards profitability. Revenue grows to approximately $135M, maintaining a healthy revenue multiple and leading to an estimated valuation of $1.62B, a 70% upside.

Bear (29%)-43%

Slower-than-expected adoption, increased competition from incumbents, or regulatory delays hinder expansion and profitability. Revenue growth stalls at around $90M, and the company faces a flat or down round, leading to a valuation of $540M. Given the $409M in liquidation preferences, this would significantly erode common stock value, resulting in a -43% downside for the company's overall valuation.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Investors hold $409M in liquidation preferences. In an exit at the current estimated $950M valuation, common shareholders would only see value from the remaining $541M. If the exit is at or below $409M, common shareholders would receive nothing.

Dilution Risk

high

As a high capital intensity company not yet profitable, Karius will likely require additional funding rounds, leading to further dilution of employee equity.

Secondary Liquidity

limited

Platforms like EquityZen offer some avenues for accredited investors to sell shares, but it is not a liquid market and access is restricted.

Commercial — 9 roles

Clinical & Medical — 4 roles

General & Administrative — 1 role

General Inquiry — 1 role

Research & Development — 1 role

View all 16 open roles at Kariusdx →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Kariusdx's data — designed to show you've done your homework.

  • 1

    “Given the strong clinical evidence for the Karius Test® and its FDA Breakthrough Device designation, what are the primary commercialization strategies to expand beyond the current 400+ hospitals and into new settings, and how will these be prioritized over the next 12-24 months?”

  • 2

    “With Karius not yet profitable and having high capital intensity, how does the company plan to manage its burn rate and achieve profitability or cash flow positivity, and what milestones are critical to reaching that goal?”

  • 3

    “Considering the $409M in total funding and the estimated current valuation, how does Karius view the path to a liquidity event for employees, and what are the company's plans regarding secondary liquidity or tender offers in the coming years?”

Community

Valuation Sentiment

Our model estimates -27% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.